-
AUSTIN, TX - Jun 27, 2016 - Bioo Scientific recently launched the NEXTflex BRCA1 and BRCA2 Amplicon Panel for FFPE Illumina-Compatible Sequencing, for the detection of clinically relevant somatic mutations in DNA isolated from FFPE samples, to facilitate variant discovery and confirmation
Jun 27, 2016
-
NEEDHAM, MA, UNITED STATES - May 26, 2016 - Cambridge Healthtech Institute (CHI) announces its inaugural DNA Forensics conference will take place on August 23-24, 2016 at the Hyatt Washington Hotel in Washington, DC-as part of the Next Generation Dx Summit
May 26, 2016
-
BOSTON, MA, UNITED STATES - May 20, 2016 - Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research
May 20, 2016
-
MUNICH, GERMANY - May 10, 2016 - Definiens, the pioneer in Tissue Phenomics® solutions for diagnostics development, has announced findings from the International Symposium, a sold-out gathering of international researchers and clinicians on April 27-28 in Boston, Massachusetts to discuss advancements in oncology and the application of Tissue Phenomics
May 10, 2016
-
LAUSANNE, SWITZERLAND - May 9, 2016 - Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal
Clinical Cancer Research
May 9, 2016
-
LONDON, UK - Mar 21, 2016 - ~~For immediate release 21 March 2016
ANGLE plc (“the Company”)
BARTS PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR PROSTATE CANCER DETECTION CLINICAL APPLICATION
Potential for a simple blood test to not only detect prostate cancer but also to assess the aggressiveness of the disease allowing risk stratification to active surveillance or intervention
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer
Mar 21, 2016
-
MUNICH, GERMANY - Mar 8, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response
Mar 8, 2016
-
LUND, SWEDEN - Dec 4, 2015 -
LUND, Sweden
― CREATE Health Translational Cancer Center, Lund, Sweden in collaboration with Immunovia today announced that they have completed a retrospective study demonstrating that the IMMray™ PanCan-d test is able to differentiate with 96% accuracy patients with early resectable stages of pancreatic cancer, stage I and II, from the healthy controls
Dec 4, 2015
-
NEEDHAM, MA, UNITED STATES - Oct 14, 2015 - For more information:Dan MillerInsight Pharma Reportsdmiller@healthtech.com781-972-5492 FOR IMMEDIATE RELEASE Insight Pharma Reports Announces Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system
NEEDHAM, MASS
Oct 14, 2015
-
NEEDHAM, MA, UNITED STATES - Jun 19, 2015 - Insight Pharma Reports' releases the
report, The Human Microbiome: Biomedical Implications and Birth of
a Market, which covers the evolution of microbiome research
and its growth in the commercial market
Jun 19, 2015
-
NEEDHAM, MA, UNITED STATES - Jun 19, 2015 - Insight Pharma Reports, a division of Cambridge Healthtech Institute, releases a new market study focusing on marketing to life scientists
Jun 19, 2015